Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Alice Bexon, MD
CMO
Study Chair - Stephen J Russell, MD, Ph.D.
Clinical Lead
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hospital Sao Rafael
Salvador, BR, Brazil
- Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, Brazil
- Inca
Rio de Janeiro, Rio de Janeiro, Brazil
- Hospital de Amor de Barretos
Barretos, São Paulo, Brazil
- Saint John'S Health Center - John Wayne Cancer Institute (jwci)
Santa Monica, California, United States
- Yale University
New Haven, Connecticut, United States
- University of Miami
Miami, Florida, United States
- Ochsner Clinic Foundation
New Orleans, Louisiana, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Billings Clinic Montana Cancer Consortium
Billings, Montana, United States
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
- University of Cincinnati Medical Center
Cincinnati, Ohio, United States
- Sanford Cancer Center
Sioux Falls, South Dakota, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Apr 2020
- Primary completion
- 31 Oct 2026
- Completion
- 31 Dec 2026
- Last update posted
- 8 Jul 2026
- Registered enrollment
- 87
- Registry id
- NCT04291105
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.